Skip to main content

Advertisement

Table 3 Lesion detection by modality

From: Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors

Primary tumor    Skeletal lesions seen   Soft tissue lesions or organ involvement   Nodes seen   
Ab dose (mg) No. of cycles Total CT scan or BS Antibody scan Total CT scan Antibody scan Total CT scan Antibody scan
Melanoma 5 2 0 0 0 3 3 3 1 1 0
Renal cell 5 4 3 3 3 6 6 4 3 3 2
Renal cell 5 4 2 2 2 9 9 4 1 1 0
Hepatocellular 10 1 0 0 0 6 6 4 0 0 0
Melanoma 10 2 4 4 0 12 12 7 3 3 2
Melanoma 10 2 1 1 0 5 5 5 3 3 3
Renal cell 10 4 0 0 0 8 7 4 2 2 1
Adenoca colon 20 2 3 3 2 12 12 10 3 3 0
Melanoma 20 2 5 5 5 8 8 2 0 0 0
SCC hypoph 20 2 0 0 0 2 2 2 1 1 1
TCC renal pelvis 20 4 0 0 0 2 2 2 1 1 0
Adenoca colon 40 1 0 0 0 2 2 1 0 0 0
TCC renal pelvis 40 2 0 0 0 1 1 1 3 3 2
Melanoma 60 2 1 1 1 8 8 3 3 3 3
Renal cell 60 1 0 0 0 5 5 4 2 2 2
Renal cell 60 4 0 0 0 6 6 3 0 0 0
Adenoca gastric 100 4 0 0 0 5 5 5 3 3 0
Breast 100 1 7 7 6 0 0 0 0 0 0
SCC tongue 100 2 1 1 1 3 3 3 0 0 0
TCC-bladder 100 2 0 0 0 6 6 3 5 5 2
    27 27a 20 109 108 70 34 34 18
  1. aTotal bone lesions detected by CT only: 13. Adenoca, adenocarcinoma; hypoph, hypopharynx; SCC, squamous cell carcinoma; TCC, transitional cell carcinoma.